This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
If someone has run Metformin co-administration properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Answering the question post #121 raises rather than the one it answers.
Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.
Agreed on Metformin co-administration, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
Insulin and sulfonylureas are the interaction that the labelling in this class flags most explicitly, because the risk is additive glucose lowering. That is a prescribing question and not a forum question.
I would treat the number as indicative rather than as a measurement.
A methods point on Metformin co-administration rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
Everything in post #125 holds. The case it does not cover is the one I have.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
The disagreement above is smaller than it looks once the terms are fixed.
Narrowing post #125, because the general version has more than one answer.
Two people in this thread mean different things by Metformin co-administration and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
This is the first time the answer has come with its own limits attached. Appreciated.
Post #128 is right about the mechanism and I think understates the practical bit.
The version of Metformin co-administration that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Quietly grateful for the plain phrasing. Not every thread gets that.
Adding the measurement that post #131 says would settle it.
I have three months of notes on Metformin co-administration and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
Post #130 describes the usual case. This is about the unusual one.
Where a published interaction study exists it usually reports an area-under-curve ratio, and that number is far more informative than a yes-or-no answer.
That holds for the case as described. Change the assumptions and it may not.
Building on post #133 rather than restating it.
The most defensible general position in this subcategory: identify the plausible mechanism, check whether it has been studied, and where it has not, say that rather than filling the gap.
That is the version I use. It may not be the version that is correct.
Where the Metformin co-administration discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
If you are new and reading this thread for the answer to Metformin co-administration: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Answering the question post #134 raises rather than the one it answers.
Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
The answer changed when I changed how I was measuring, which was informative.
Coming back to post #138, because the follow-up matters more than the original answer.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
That is where I would start, not where I would stop.
Bookmarking this. I will come back when I have something worth adding.
Metformin: commonly co-administered and relevant to gastrointestinal tolerability. Gastrointestinal side effects can overlap and additive. Taking them separately or adjusting one if tolerability is poor are reasonable approaches.
I have left out the parts I could not verify.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Sulfonylureas: the interaction most worth taking seriously — what changed since
On the subject in the title: Sulfonylureas: the interaction most worth taking seriously — what changed since Working notes rather than a conclusion. What changes if the standard account of Sulfonylureas is…
|
+3 | 7 | 35k | 1d |
|
[2026 update] Antibiotics and a course of something with delayed emptying
On the subject in the title: Antibiotics and a course of something with delayed emptying Working notes rather than a conclusion. Something changed and I would like to know whether it should have. Same…
|
+88 | 97 | 19k | 13h |
|
About the Interactions category
Drug, supplement and food interactions — separating timing inconveniences from clinically important ones. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+4 | 8 | 1.9k | 2mo |
|
Grapefruit: why this class is not the class that cares
Grapefruit: why this class is not the class that cares Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about grapefruit in a thread last spring and I would like…
|
+126 | 139 | 4k | 4mo |
|
Delayed gastric emptying and oral medication absorption: which drugs matter — one year on
On the subject in the title: Delayed gastric emptying and oral medication absorption: which drugs matter — one year on Working notes rather than a conclusion. A follow-up question about Delayed gastric…
|
3 | 16k | 2mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
IGF-1 as a surrogate endpoint and its limitations — the long version
On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. A narrow question about IGF-1, deliberately narrow, because the broad…
|
+14 | 18 | 53k | 12mo |
|
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs matter
Delayed gastric emptying and oral medication absorption: which drugs matter Writing it up because I had to work it out twice and would rather nobody else did. Reading back through what has been written here…
|
+63 | 74 | 11k | 1d |
|
Dizziness on standing and the electrolyte explanation
On the subject in the title: Dizziness on standing and the electrolyte explanation Working notes rather than a conclusion. Trying to work out what would count as evidence on dizziness on standing, before…
|
+3 | 7 | 147 | 4mo |
|
The nausea timeline across the first four weeks, with a tabulated log — what changed since
On the subject in the title: The nausea timeline across the first four weeks, with a tabulated log — what changed since Working notes rather than a conclusion. What changes if the standard account of nausea…
|
+24 | 29 | 2.8k | 6mo |
|
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin oral versus injected administration claims…
|
+20 | 24 | 47k | 4mo |